Create Account

One Health helps you track and understand your health simply.

Create Account

One Health helps you track and understand your health simply.

Phenobarbital

Immunology & Autoimmune

PBPhenobarbital serum concentrationPhenobarbitone level

Review status

Currently under review

Pending specialist review and validation.

What it shows

This test measures the amount of phenobarbital in your blood. Phenobarbital is a long-acting anticonvulsant and sedative used to prevent seizures and to manage certain withdrawal states. Because the drug’s helpful effects and side effects are closely tied to how much is in your bloodstream, checking the level helps tailor treatment to you.

Clinicians use this as a therapeutic drug monitoring test. It is usually drawn at a consistent time in relation to dosing, often when the medication is at its lowest level in the blood, to guide dosing and assess adherence, interactions, and safety.

Why it matters

Keeping phenobarbital within an individualized therapeutic window helps control seizures while reducing side effects like excessive sleepiness, problems with coordination, or mood changes. Your level can change with dose adjustments, missed doses, interactions with other medicines, and changes in health, so measuring it helps your clinician make informed decisions.

This test is often ordered after starting therapy, after dose changes, when adding or stopping interacting drugs, during pregnancy, with signs of toxicity or loss of seizure control, and in liver disease. It can also be important for children and older adults, who may process the drug differently.

Understanding your results

Your clinician will interpret your level alongside how you feel, when the blood was drawn relative to your last dose, and other lab and clinical information. If the level is lower than expected and you are still having seizures, your care team may adjust the dose or timing, or check for missed doses or drug interactions. If the level is higher than expected or you have side effects such as marked drowsiness or unsteady gait, they may reduce the dose, change the schedule, or consider another medicine.

Do not change your dose on your own. If you have new or worsening symptoms, contact your clinician. Future levels are often drawn at similar times and under similar conditions so results can be compared reliably.

Reference ranges

65175 umol/L
All sexes
0 days – 150 years

Reference intervals vary by laboratory, analyzer, methodology, population, and units. The ranges shown here are for education only. Always interpret your results against the reference interval printed on your own lab report.

Factors that could impact Phenobarbital

  • Timing of the blood draw

    Levels should be drawn consistently in relation to your dosing, commonly as a trough just before the next dose. Drawing at different times can make results hard to compare.

  • Drug interactions

    Medicines such as valproate, carbamazepine, phenytoin, and certain antibiotics can raise or lower phenobarbital levels. Always tell your clinician and pharmacist about all prescriptions, over-the-counter drugs, and supplements.

  • Liver function and age

    Phenobarbital is processed by the liver. Liver impairment, as well as very young or older age, can change how quickly the drug is cleared, affecting blood levels and dosing needs.

  • Pregnancy

    Body changes in pregnancy can increase drug clearance and lower levels. Regular monitoring helps maintain seizure control while balancing safety for you and the fetus.

  • Adherence and formulation changes

    Missed doses, taking extra doses, or switching between brands or formulations without guidance can shift levels and alter seizure control or side effects.

  • Alcohol and sedation risk

    Alcohol and other sedatives can add to phenobarbital’s effects, increasing sleepiness and safety risks. Avoid mixing without medical advice and report any changes in use.

2026

References

  1. McGill University Health Centre. (2017, August 22). Phenobarbital (Task CD 317092). Laboratory reference ranges.
  2. Patsalos, P. N., Berry, D. J., Bourgeois, B. F. D., Cloyd, J. C., Glauser, T. A., Johannessen, S. I., Tomson, T., & Perucca, E. (2018). Antiepileptic drugs: A clinically useful therapeutic drug monitoring in epilepsy update. Epilepsia, 59(9), 1559–1571.